The latest medical insurance policy updates for the cholangiocarcinoma targeted drug ivonib

Ivonib, also known as ivitinib, is a targeted drug targeting isocitrate dehydrogenase-1 (IDH1) mutation. It is mainly used to treat IDH1 mutant acute myeloid leukemia (AML), cholangiocarcinoma and myelodysplastic syndrome (MDS). The drug inhibits abnormal IDH1 protein activity, thereby reducing the production of the carcinogen 2-hydroxyglutarate (2-HG) and slowing down tumor growth and metastasis. However, the high price of ivonib has caused widespread concern among patients and their families as a result of its medical insurance issues.

According to the latest policy information, avonib has not yet been included in my country’s medical insurance catalog. This situation means that patients need to bear the entire cost when using the drug, which is undoubtedly a huge financial burden for many patients. Therefore, patients and their families are very concerned about the changes in the medical insurance policy of ivonib and hope that it can be included in the medical insurance as soon as possible to reduce the pressure on medical expenses.

Although there is no clear information that ivosidenib will be added to the medical insurance, with the continuous improvement of the national medical insurance system and the rapid development of the pharmaceutical market, it is possible that ivosidenib will be included in the medical insurance catalog in the future to provide financial support to more patients. Patients and their families should stay tuned and obtain relevant policy updates in a timely manner so that they can benefit quickly when policies change.

It should be pointed out that although the price of the original drug of ivonib is relatively high, a generic drug produced by Laos Lucius Pharmaceutical Company has appeared on the overseas market. The price of the product of the same specification is about more than 4,000 yuan, which is relatively more affordable. This provides another feasible treatment avenue for patients with limited financial conditions. However, when purchasing generic drugs, patients must ensure that they choose formal purchasing channels to ensure the quality and safety of the drugs.

In summary, as an important targeted therapeutic drug, ivonib has significant clinical value in the treatment of cancers related to IDH1 mutations such as cholangiocarcinoma. Although its high price has caused certain pressure on medical insurance, with the continuous adjustment of policies and changes in the market environment, it is expected to provide more financial support to patients in the future. Patients should pay close attention to the latest developments in medical insurance policies, and carefully choose drugs and purchase channels based on their own conditions to ensure efficacy and safety.

References:

https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo